Lilly, Boehringer Ingelheim get expanded Synjardy indication

SILVER SPRING, Md. — Eli Lilly & Co. and Boehringer Ingelheim announced Tuesday that the Food and Drug Administration had approved an expanded indication for their Synjardy (empagliflozin and metformin hydrochloride) tablets. 

 

The new indication makes the drug available for treatment-naïve adults with type 2 diabetes as an adjunct to diet and exercise as a way of improving glycemic control. 

 

"Type 2 diabetes is a complex condition, which often requires that people take more than one treatment to manage their blood sugar," Boehringer Ingelheim president and CEO Paul Fonteyne said. "The expanded indication for Synjardy further validates the potential of this combination therapy to help adults with type 2 diabetes who are not at goal, including those already being treated and, now, those at the beginning of their treatment journey."